Does PACAP 38 Work Differently Than CGRP?
Migraine Minute News Update
New research shows CGRP monoclonal antibody treatment may not prevent migraine attacks triggered by the neuropeptide PACAP-38. This study suggests PACAP-38 may act through a different pathway and could become a future preventive option for people who don’t respond to CGRP-based treatments. Molly O’Brien explains in this Migraine Minute News Update. Read More: Images courtesy: Springer Nature. The Journal of Headache and Pain. doi: 10.1186/s10194-025-02022-2 Creative Commons license: Script: Does PACAP 38 Work Differently Than CGRP? A new study published in the Journal of Headache...
info_outline
Can Erenumab Treat Medication Overuse Headache?
Migraine Minute News Update
A study published in JAMA Neurology shows that monthly erenumab injections may help treat medication overuse headache (MOH) in people with chronic migraine. While the 140 mg dose was effective for treating MOH, the 70 mg dose did not show a meaningful difference compared to placebo. Molly O’Brien explains in this Migraine Minute News Update. Read More: Image Courtesy: JAMA Neurology doi:10.1001/jamaneurol.2024.3043 Transcript: A study published in JAMA Neurology looked at the safety and efficacy of a CGRP monoclonal antibody for treating Medication Overuse Headache in people with...
info_outline
Predicting if a Preventive Migraine Treatment Will Work
Migraine Minute News Update
Most people with migraine go through trial and error to find a preventive treatment that works. But researchers at the Mayo Clinic may have found a way to change that. Using AI, they developed a tool to predict how someone might respond to certain migraine medications—particularly CGRP monoclonal antibodies. Molly O’Brien has more in this Migraine Minute News Update. Read More:
info_outline
Can This Preventive Drug Bring Immediate Migraine Relief?
Migraine Minute News Update
Rapid relief from a preventive migraine treatment? A study published in Neurology shows that one oral gepant medication may start working right away to prevent migraine attacks. Molly O’Brien fills you in, in this Migraine Minute News Update. Read more:
info_outline
FDA Approves Axsome’s New Migraine Drug Symbravo®
Migraine Minute News Update
The FDA has approved a new drug for the acute treatment of migraine with or without aura in adults. Molly O’Brien has the details and when it becomes available in this Migraine Minute News update. Learn More:
info_outline
Can CGRP Blocking Drugs Help Endometriosis?
Migraine Minute News Update
Researchers in Boston found that CGRP-blocking drugs commonly used for migraine may help with endometriosis pain and lesion size. Molly O’Brien has the details in this Migraine Minute news update recognizing Endometriosis Awareness Month. Read More: https://bit.ly/4jp0cG2 AMD Comorbidities Library: https://bit.ly/3CIrLtd
info_outline
Cluster Headache Often Coexists with Fibromyalgia & Migraine
Migraine Minute News Update
Cluster Headache Awareness Day is March 21st. In this Migraine Minute News Update Molly O’Brien explains findings from a study that found cluster headache, fibromyalgia, and migraine are frequently comorbid conditions. Learn More:
info_outline
Ubrogepant Reduced Migraine-Related Limitations When Taken During the Prodrome Phase
Migraine Minute News Update
According to a study published in Neurology, when compared to placebo, this gepant led to significantly greater ability to function normally and a greater reduction in activity limitation when taken during the prodrome phase of an attack. Molly O’Brien has the details in this Migraine Minute News Update. Read More: https://bit.ly/3BY2J9d
info_outline
FDA Clears Nerivio Device for Children 8+
Migraine Minute News Update
Kids age 8+ now have access to a non-drug migraine treatment option. In this Migraine Minute News Update, Molly O’Brien explains the FDA clearance of Theranica’s Nerivio device for acute and preventive migraine treatment in kids. Read more:
info_outline
MERTK as a Potential Novel Target for Cluster Headache
Migraine Minute News Update
Researchers have identified elevated levels of the gene MERTK, (which is linked to cluster headaches) and its ligand Gal-3, in the nerve tissues of rats and in blood samples of people with cluster headache. In this Migraine Minute News Update Molly O’Brien breaks down what it means for people living with Cluster. Read More:
info_outlineA study published in JAMA Neurology shows that monthly erenumab injections may help treat medication overuse headache (MOH) in people with chronic migraine. While the 140 mg dose was effective for treating MOH, the 70 mg dose did not show a meaningful difference compared to placebo.
Molly O’Brien explains in this Migraine Minute News Update.
Read More: https://bit.ly/4jCusxk
Image Courtesy: JAMA Neurology doi:10.1001/jamaneurol.2024.3043
Transcript:
A study published in JAMA Neurology looked at the safety and efficacy of a CGRP monoclonal antibody for treating Medication Overuse Headache in people with chronic migraine.
Results show that erenumab– sold under brand name Aimovig- can lead to lasting remission of MOH, reduce the need for pain medication, and improve daily functioning over six months.
The study included 584 people with chronic migraine who also had medication overuse headache. At 6 months, 69.1% of those who received 140 mg injections of erenumab monthly no longer met the criteria for medication overuse headache compared to 52.6% of people in the placebo group.
It should be noted that the study did not include people who had medication-overuse headache from opioid use.